ClinicalTrials.gg
RecruitingNCT06688201MIRACLE-LUpdated Jan 7, 2025

Minimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage-- Large Hemorrhage Evacuation (MIRACLE-L)

An interventional study of Other neurosurgical techniques and Minimally Invasive Soft Channel Brain Haemorrhage Evacuation in Intracerebral Hemorrhage, sponsored by Capital Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.

Planned enrollment
18th of 77
550 · median 180
Started
2025
with 19 others
No phase
35 of 123
22 open now
Primary completion
2026-11
later than 22 of 61 live
Registered
84th of 123
by date
Lead sponsor
9 of 123
Capital Medical University

Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 18th largest by planned enrollment of the 77 interventional ones that give a count, is one of 20 that started in 2025, is one of 35 with no phase, reaches primary completion later than 22 of the 61 other live ones, and was the 84th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Cerebral Hemorrhage with a site in China, or all of them as a file.
02

Study summary

To determine if minimally invasive soft channel brain hemorrhage evacuation (scMIS), compared with any other neurosurgical technique that includes open craniotomy, small skull window microsurgery , and endoscopic surgery, is at least as effective ('not inferior') on poor clinical outcome of death or major disability (mRS scores 4-6) at 6 months in basal ganglia intracerebral hemorrhage (ICH) of 30 \< volume ≤ 100 ml.

03

Conditions studied

  • Intracerebral Hemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (18 - 80 years) ;

    1. The clinical diagnosis is acute intracerebral hemorrhage, confirmed by imaging;
    2. Onset within 48 hours, and surgery can be initiated within 48 hours;
    3. Basal ganglia hemorrhage, with a bleeding volume of 30 \< volume ≤ 100 ml;
    4. Reduced level of consciousness (GCS 4-14);
    5. Pre-stroke mRS score≤1 points;
    6. Systolic blood pressure \<140 mmHg before randomisation;
    7. Availability of being able to receive either scMIS or other neurosurgical technique;
    8. obtain accordingly to local regulations.

Exclusion criteria

  1. Definite evidence the ICH is secondary to a structural abnormality in the brain (eg arteriovenous malformation, intracranial aneurysm, tumour, trauma, cerebral venous thrombosis) or previous thrombolysis or neurointerventional surgery.

    1. A high likelihood that the patient will not adhere to the study treatment and follow-up regimen.
    2. count \< 100,000, > 1.4.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Other
    Other neurosurgical techniques

    Those include open craniotomy, small skull window microsurgery, and endoscopic surgery.

    Other: Other neurosurgical techniques

  • Experimental
    Minimally Invasive Soft Channel Brain Haemorrhage Evacuation

    Minimally Invasive Soft Channel Brain Haemorrhage Evacuation

    Procedure: Minimally Invasive Soft Channel Brain Haemorrhage Evacuation

Interventions

  • OtherOther neurosurgical techniques

    Those include open craniotomy, small skull window microsurgery, and endoscopic surgery. The attending clinician is required to consider which type of craniotomy or other procedure according to the expertise and availability at the hospital.

  • ProcedureMinimally Invasive Soft Channel Brain Haemorrhage Evacuation

    This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.

06

What researchers measure

Primary outcomes

  1. The primary outcome is death or major disability (mRS scores 0-3) at 6 months.

    Ordinal analysis of modified Rankin Scale \[mRS\] score: 0 =No symptoms at all.1 =No significant disability despite symptoms, able to carry out all usual duties and activities.2 =Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance.3 =Moderate disability requiring some help, but able to walk without Assistance. 4 =Moderate severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance.5 =Severe disability, bedridden incontinent, and requiring constant nursing care and attention.6 =Dead.

    Time frame: 6 months after randomization

Secondary outcomes

  1. Discharge at Day 7 (yes vs. no)

    Discharge status will be assessed at Day 7

    Time frame: 7 days after randomization

  2. Total length of intensive care unit stay

    The complete length of time a patient is admitted to the intensive care unit (ICU)

    Time frame: During hospitalisation up to 6 months after randomization

  3. Ordinal analysis of modified Rankin Scale [mRS] scores at 28 days

    Ordinal analysis of modified Rankin Scale \[mRS\] score: 0 =No symptoms at all.1 =No significant disability despite symptoms, able to carry out all usual duties and activities.2 =Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance.3 =Moderate disability requiring some help, but able to walk without Assistance. 4 =Moderate severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance.5 =Severe disability, bedridden incontinent, and requiring constant nursing care and attention.6 =Dead.

    Time frame: 28 days after randomization

  4. The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 3-6

    Proportion of subjects with modified Rankin Scale \[mRS\] 3-6 at 6 months after randomization.

    Time frame: 6-months after randomization

  5. The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 3-5

    Modified Rankin Scale \[mRS\] score at 6 months analysed as an ordinal outcome (categories 3 to 5).

    Time frame: 6-months after randomization

  6. The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 0-6

    Modified Rankin Scale \[mRS\] score at 6 months analysed as an ordinal outcome (categories 0 to 6).

    Time frame: 6-months after randomization

  7. The following at 6-months: AMC Linear Disability Score(ALDs)

    The AMC (Academic Medical Center) Linear Disability Score (ALDs) is a calibrated generic item bank designed to measure physical disability levels in patients. The ALDs is a sensitive and generic scale that encompasses a broader range of activities compared to the Rankin assessment. The key distinction between the ALDs and the Rankin assessment is that the ALDs provides a linear disability score based on patient-reported outcomes, while the Rankin score is an ordinal assessment determined by a rater.

    Time frame: 6-months after randomization

  8. The following at 6-months: EuroQoL Group 5-Dimension self-report questionnaire (EQ-5D)

    An EQ-5D score, also referred to as an EQ-5D value index or utility, quantifies a person's health status on a scale from 1 (full health) to 0 (equivalent to being dead). Negative values may be assigned to health states considered worse than death.The score is calculated using a formula that applies specific weights to each level in the various dimensions of the EQ-5D, with these weights derived from a value set that includes index values for all possible EQ-5D states.

    Time frame: 6-months after randomization

  9. Days of hospitalization

    Length of stay in hospital.

    Time frame: During hospitalisation up to 6 months after randomization

Other outcomes

  1. Safety outcomes

    Mortality, rebleeding, infections, and other serious adverse events (SAEs) recorded throughout the entire study period.

    Time frame: Throughout the entire study period up to 6 months after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2026, 22 months after the start.

Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 22 months is below that.

Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Nov 14, 2024
StartActual
Jan 4, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06688201
Collaborators
Linyi People's Hospital, Fudan University
Responsible party
Ji Xunming,MD,PhD (Professor ,Beijing Institute of Brain Disorders,Captial Medcial University, Capital Medical University) — Principal investigator
First posted
Nov 14, 2024
Start date
Jan 4, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 7, 2025

Study contacts

XunMing Ji, PhD
Contact
jixm@ccmu.edu.cn
+8613911077166
HeTao Bian, PhD
Contact
hetaobian@163.com
+8618210706812
XunMing Ji, PhD
principal investigator · Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion